Literature DB >> 3306281

Human blood-brain barrier transferrin receptor.

W M Pardridge, J Eisenberg, J Yang.   

Abstract

The kinetics of binding and endocytosis of 125I-human holotransferrin by isolated human brain capillaries was examined using this system as a model of the human blood-brain barrier (BBB). Both binding and endocytosis of the peptide by human brain capillaries was temperature-dependent and the binding was saturated by holotransferrin, but not by insulin, somatostatin, or vasopressin. Scatchard analysis of the binding reaction revealed a dissociation constant of 448 +/- 110 ng/mL (5.6 +/- 1.4 nmol/L) and a maximal binding constant (Ro) of 8.0 +/- 1.5 ng/mg protein. Thus, the affinity and capacity of the BBB transferrin receptor is within the same order of magnitude as the affinity and capacity of the BBB receptors for insulin, insulinlike growth factor-I, or insulinlike growth factor-II. The human brain capillary transferrin receptor was also detected with a mouse monoclonal antibody to the receptor using the avidin/biotin/peroxidase technique. In conclusion, these studies characterize the human BBB transferrin receptor and support the hypothesis that this receptor acts as a transport system which mediates the transcytosis of transferrin-bound iron through the brain capillary endothelial cell in man.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3306281     DOI: 10.1016/0026-0495(87)90099-0

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  68 in total

Review 1.  Reoxygenation injury of human brain capillary endothelial cells.

Authors:  T Nagashima; S Wu; M Yamaguchi; N Tamaki
Journal:  Cell Mol Neurobiol       Date:  1999-02       Impact factor: 5.046

2.  Carboxyl-directed pegylation of brain-derived neurotrophic factor markedly reduces systemic clearance with minimal loss of biologic activity.

Authors:  T Sakane; W M Pardridge
Journal:  Pharm Res       Date:  1997-08       Impact factor: 4.200

3.  Development of transferrin functionalized poly(ethylene glycol)/poly(lactic acid) amphiphilic block copolymeric micelles as a potential delivery system targeting brain glioma.

Authors:  Wei-hua Ren; Jiang Chang; Cheng-hu Yan; Xiao-min Qian; Li-xia Long; Bin He; Xu-bo Yuan; Chun-sheng Kang; Didier Betbeder; Jing Sheng; Pei-yu Pu
Journal:  J Mater Sci Mater Med       Date:  2010-06-10       Impact factor: 3.896

4.  Nanomedicine in the diagnosis and therapy of neurodegenerative disorders.

Authors:  A V Kabanov; H E Gendelman
Journal:  Prog Polym Sci       Date:  2007       Impact factor: 29.190

5.  Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier.

Authors:  P M Friden; L R Walus; G F Musso; M A Taylor; B Malfroy; R M Starzyk
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-01       Impact factor: 11.205

Review 6.  Strategies to improve drug delivery across the blood-brain barrier.

Authors:  Albertus G de Boer; Pieter J Gaillard
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 7.  Blood-brain barrier transport of therapeutics via receptor-mediation.

Authors:  Angela R Jones; Eric V Shusta
Journal:  Pharm Res       Date:  2007-07-10       Impact factor: 4.200

8.  Differential tissue localization of oviduct and erythroid transferrin receptors.

Authors:  H A Fuernkranz; J E Schwob; J J Lucas
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205

9.  Anti-cancer Antibody Trastuzumab-Melanotransferrin Conjugate (BT2111) for the Treatment of Metastatic HER2+ Breast Cancer Tumors in the Brain: an In-Vivo Study.

Authors:  Mohamed Ismail Nounou; Chris E Adkins; Evelina Rubinchik; Tori B Terrell-Hall; Mohamed Afroz; Tim Vitalis; Reinhard Gabathuler; Mei Mei Tian; Paul R Lockman
Journal:  Pharm Res       Date:  2016-08-15       Impact factor: 4.200

10.  Transferrin-antibody fusion proteins are effective in brain targeting.

Authors:  S U Shin; P Friden; M Moran; T Olson; Y S Kang; W M Pardridge; S L Morrison
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.